Disease evidence hub
A curated view of published Tuberculosis research, auditable classifier relationships, and its publication timeline.
Evidence timeline
Monthly publication counts from the catalogue show how research activity changes over time.
24 publication months · peak 2026-10 (38)Guidance and policy markers identify dated publications in the curated catalogue; they do not by themselves establish that an official policy changed on that date.
Evidence stream
30 of 551 publications shown
The American Journal of Tropical Medicine and Hygiene
Why it matters now The findings support including cervical tuberculosis in the differential diagnosis of cervical lesions, particularly in tuberculosis-endemic settings, because its presentation may be nonspecific and mimic malignancy.
Antimicrobial Agents and Chemotherapy
Why it matters now The findings may inform future tuberculosis drug combinations by exploiting respiratory-chain collateral vulnerability, supporting pipeline expansion beyond standalone agents.
Nature
Why it matters now Per the abstract, the framework advances understanding of tuberculosis biology and may inform rational design of combination therapies against M. tuberculosis, described in the abstract as the world's deadliest pathogen.
Microbiology Spectrum
Why it matters now The study addresses a diagnostic problem because elevated-nil indeterminate QuantiFERON results may delay or prevent appropriate LTBI care. The authors associate repeat IGRA testing with improved LTBI detection and timely chemoprophylaxis, although downstream clinical outcomes were not reported in the abstract.
Microbiology Spectrum
Why it matters now The abstract frames MDR-TB spread as a control challenge where rapid molecular drug-susceptibility testing is often unavailable, and presents the assay as a potential low-complexity screening option for selected resistance mutations.
WHO Institutional Repository (IRIS)
Why it matters now The annex is intended to support standardized interpretation of genetic mutations associated with antituberculosis drug resistance. Its abstract specifies that the list should be used with additional grading and interpretation criteria in an automated, quality-assured sequencing analysis framework.
The Medical journal of Australia
Why it matters now The case highlights the importance of maintaining diagnostic vigilance for multiple concurrent conditions in complex presentations, particularly when patients do not respond to initial therapy. The limited sensitivity of traditional tuberculosis tests in extrapulmonary disease is demonstrated.
Diagnostic Microbiology and Infectious Disease
Why it matters now In non-endemic regions, constrained mycological testing may contribute to wrong diagnoses, and concurrent infections pose challenges.
Frontiers in Cellular and Infection Microbiology
Why it matters now The study addresses diagnostic uncertainty in tuberculosis and non-tuberculous mycobacterial infections by assessing mNGS as a complementary approach that may improve detection and inform clinical management when standard tests are inconclusive.
SN Comprehensive Clinical Medicine
Why it matters now Integrating rapid detection, treatment selection, monitoring, and equitable access within a resilient pathway is key to reducing DR-TB burden in the Philippines.
Microbiology Spectrum
Why it matters now Rapid automated platforms may aid high-volume settings by shortening turnaround versus conventional susceptibility testing, supporting faster MDR-TB identification.
BMC Public Health
Why it matters now Substantial pre-diagnostic delay and cost burden persist despite free testing, suggesting referral strengthening and public-center awareness efforts are needed to support End TB aims.
BMC Pulmonary Medicine
Why it matters now Routine nutritional assessment and support in drug-resistant TB care is highlighted as important for immune recovery and longer-term health.
South African Health Review
Why it matters now The assessment identifies where data constraints break learning cycles and proposes governance and surveillance strengthening so indicators can drive improvement rather than only describe it.
Curationis
Why it matters now The developed model highlights targets such as treatment attitudes and healthcare worker efforts to curb default, potentially limiting community transmission and MDR-TB risk per the authors' contribution statement.
Frontiers in Pharmacology
Why it matters now Drug-resistant TB is a major health burden, and improved computational frameworks may support future development of more effective therapeutics.
Frontiers in Public Health
Why it matters now The increasing global load of resistant TB highlights a need for region- and population-specific intervention research, especially in high-middle SDI settings.
Media Publikasi Promosi Kesehatan Indonesia
Why it matters now Active case finding detected a TB case and indicated that behavioural and environmental controls should be combined in such schools.
Journal of Endocrinology, Tropical Medicine, and Infectious Disease (JETROMI)
Why it matters now Supporting adherence via education, counselling, and monitoring may help improve patient-centered outcomes in TB care.
mSystems
Why it matters now In high-burden endemic settings, simple SNP-threshold clustering may misrepresent transmission; phylogenetic methods respecting descent are advised for accurate cluster delineation.
mSystems
Why it matters now The principal contribution is conceptual, suggesting pathogen genomes could help evaluate immune restoration against tuberculosis in treated HIV infection.
ASM Case Reports
Why it matters now Clinicians should maintain suspicion for GUTB in sterile pyuria to avoid delayed diagnosis and severe deterioration.
PLOS Neglected Tropical Diseases
Why it matters now Reducing stigma and improving community awareness with biomedical access may support timelier care for leprosy-affected populations in similar settings.
mBio
Why it matters now The findings suggest that tuberculosis relapse following a cure diagnosis may require re-treatment with caseum-penetrating antibiotics such as rifamycins, and that experimental models may better reflect clinical relapse when cure is confirmed at treatment completion.
Journal of Clinical Microbiology
Why it matters now The approach may help separate TB from NTM lung disease quickly, supporting appropriate treatment selection where diagnostic capacity is limited.
mBio
Why it matters now The authors state the findings have implications for understanding resistance evolution in the host and for designing treatment strategies against drug-resistant tuberculosis, per the abstract and classifier topics.
Bulletin of the National Research Centre
Why it matters now MDR/RR-TB remains a major contributor to antimicrobial resistance mortality. Resistance to the newest agents is already appearing, and diagnostic capacity for rapid resistance testing is distributed unevenly. The authors propose a feedback system linking rapid sequencing, individualized regimens, real-time toxicity and resistance monitoring, and population-level genomic surveillance, with equitable access as a foundation.
Infectious Diseases of Poverty
Why it matters now The elevated fluoroquinolone resistance observed in newly diagnosed individuals highlights a critical need for better antibiotic management and broader susceptibility testing. These insights offer vital data for shaping national tuberculosis control initiatives and addressing surveillance gaps.
The Egyptian Journal of Bronchology
Why it matters now Suboptimal adherence is a local concern, and the work identifies weak model-based predictors of adherence-related skills among Indonesian TB patients.
The American Journal of Tropical Medicine and Hygiene
Why it matters now In a diabetes-prevalent region, overlapping CT features may delay correct therapy, so microbiological testing remains essential to guide treatment.
